In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Xoma Corp (XOMA), with a price target of $25. The company’s shares opened today at $14.93.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -7.9% and a 34.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $27.50, implying an 84.2% upside from current levels. In a report issued on May 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Xoma Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $1.88 million. In comparison, last year the company had a GAAP net loss of $3.81 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
